Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study

Autor: Coiffier, Bertrand *, Li, Weimin *, Henitz, Erin D *, Karkera, J.D. *, Favis, Reyna *, Gaffney, Dana *, Shapiro, Alice *, Theocharous, Panteli *, Elsayed, Yusri A *, van de Velde, Helgi *, Osmanov, Evgenii A *, Hong, Xiaonan *, Scheliga, Adriana *, Offner, Fritz C., Rule, Simon *, Teixeira, Adriana C *, Walewski, Jan, de Vos, Sven, Crump, Michael, Shpilberg, Ofer *, Zinzani, Pier Luigi, Cakana, Andrew Z *, Esseltine, Dixie-Lee, Mulligan, George *, Ricci, Deborah S *
Zdroj: In Blood 18 November 2011 118(21):265-265
Databáze: ScienceDirect